Multi-Organ In Vivo CAR Vector Copy Number (VCN) Biodistribution Assay Service

Q: Is this assay suitable for in vivo CAR gene delivery systems?

Yes, the assay is specifically optimized for in vivo CAR platforms, including viral and non-viral gene delivery systems. It provides robust quantitative support for evaluating transduction efficiency, tissue targeting specificity, and potential off-target biodistribution

Online Inquiry

Background Service What We Can Offer Workflow Highlights FAQs Contact

To facilitate preclinical assessment of in vivo CAR constructs and gene-edited therapeutic agents, Creative Biolabs has developed a VCN biodistribution assay covering multiple tissues in live animal models. The platform overcomes several prominent technical limitations: undefined systemic vector distribution patterns, poor quantitation of sustained vector presence throughout organs, inadequate resolution to identify low-copy genomic integration, and unknown off-target tissue tropism of delivery vectors. It enables precise quantification of vector copy number across major organs using advanced quantitative polymerase chain reaction and droplet digital polymerase chain reaction technologies.

Introduction

Multi-organ vector copy number biodistribution analysis is a critical component in evaluating the safety and performance of in vivo CAR and gene delivery systems. Recent studies in animal models demonstrate that vector persistence varies significantly across lymphoid and non-lymphoid tissues, making precise quantification essential for risk assessment and therapeutic optimization. Using highly sensitive quantitative polymerase chain reaction and droplet digital polymerase chain reaction methods, VCN profiling enables accurate mapping of vector integration and supports regulatory-grade biodistribution evaluation in translational gene therapy development.

Our Service

Creative Biolabs delivers a biodistribution assessment solution designed to quantify vector genome integration and persistence across multiple tissues. We integrate high-performance molecular testing systems and professional pharmacokinetic data deciphering to offer clients practical analytical findings on tissue-specific delivery efficacy, undesired vector distribution, and systemic vector metabolic clearance. Our rigorous methodology ensures that low-abundance vector sequences are precisely detected even within deep tissues, mapping the physical footprint of your therapeutic candidates with absolute clarity. To fully support candidate selection and preclinical development decisions, our key capabilities include quantitative VCN profiling across major organs and peripheral blood, alongside comparative distribution mapping across sequential time points.

Discover How We Can Help - Request a Consultation.

What We Can Offer

Creative Biolabs provides integrated analytical platforms tailored for VCN biodistribution assessment in preclinical models.

Ultra-sensitive quantitative PCR for vector genome detection.
Droplet digital PCR for absolute copy number quantification.
Tissue-level genomic DNA extraction and quality control pipelines.
Multi-organ sampling panels covering systemic and lymphoid tissues.
Cross-model compatibility for rodent and non-human primate studies.

Our Workflow

Clients should provide preclinical study design including species, administration route and sampling time points, diverse tissue and blood samples, and vector sequences to support primer and probe development.

Workflow of Multi-Organ In Vivo CAR Vector Copy Number (VCN) Biodistribution Assay. (Creative Biolabs Original)

Benefits

End-to-end customized study design for multi-organ VCN biodistribution analysis based on vector type, delivery route, and study objectives.
High-sensitivity quantitative polymerase chain reaction and droplet digital polymerase chain reaction-based absolute quantification of vector copy number across major organs and blood.
Flexible multi-species support including rodent and non-human primate models for translational relevance.

FAQs

Q1: What is the sensitivity of VCN detection in multi-organ studies?

A1: The assay enables detection of extremely low-copy vector sequences using droplet digital polymerase chain reaction, making it highly suitable for early-stage biodistribution studies where transgene abundance may be minimal. This level of sensitivity supports confident evaluation of off-target exposure and rare tissue distribution events across major organs.

Q2: Can this assay differentiate between episomal and integrated vector DNA?

A2: The assay primarily quantifies total vector copy number (VCN) within genomic DNA. However, study design can be further optimized to focus on integration-related analysis when required, enabling more detailed interpretation of vector persistence and genomic incorporation behavior.

Q3: Which animal models are compatible with this service?

A3: The workflow is fully compatible with both rodent models (such as mouse and rat systems) and non-human primate studies. This flexibility ensures translational relevance across early discovery, preclinical validation, and advanced in vivo CAR development programs.

Q4: Is this assay suitable for in vivo CAR gene delivery systems?

A4: Yes, the assay is specifically optimized for in vivo CAR platforms, including viral and non-viral gene delivery systems. It provides robust quantitative support for evaluating transduction efficiency, tissue targeting specificity, and potential off-target biodistribution.

Partner with Us

Creative Biolabs provides a high-resolution Multi-Organ In Vivo CAR Vector Copy Number (VCN) Biodistribution Assay designed to support preclinical evaluation of gene therapy and in vivo CAR programs. By delivering precise, reproducible, and organ-specific quantitative insights, the service helps researchers better understand vector behavior, improve safety assessment, and optimize therapeutic design strategies. For detailed project consultation, customized study design, or technical support, our scientific team is ready to assist you with tailored solutions based on your research needs. Connect with our team to learn more and go through your project together.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.